#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Pneumonia Vaginal cancer Skin angiosarcoma Non-Hodgkin's lymphoma refractory Acute respiratory distress syndrome Aspergillus infection Infantile spasms Anti-HLA antibody test positive Neurodermatitis IPEX syndrome Blastic plasmacytoid dendritic cell neoplasia Infantile apnoea Congenital megacolon Leukoencephalopathy Hodgkin's disease recurrent More trials…

    Learn about Rare Diseases

    Noonan syndrome – Life with Disease Combined immunodeficiency – Basic Information Alport’s syndrome – Basic Information Cholangitis sclerosing Cytokine release syndrome – Basic Information Prolymphocytic leukaemia – Diagnostics Acute respiratory distress syndrome – Diagnostics Rhabdoid tumour IgA nephropathy – Trials in Disease Idiopathic pulmonary fibrosis – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Artemisia Vulgaris (312) Cebsulfase Alfa Dapagliflozin Propanediol AB521 Frexalimab Omp72 HYDROMORPHONE HYDROCHLORIDE Ima203Cd8 Codeine Phosphate Hemihydrate Glenzocimab Methylprednisolone Moxifloxacin L-METHIONINE Crofelemer Levoleucovorin Tiaprofenic Acid Levocetirizine Dihydrochloride SPY002 Ezabenlimab IM-101 More therapies…

    Learn about Your Condition

    Biliary adenoma Pruritus Hepatic angiosarcoma Cardiac valve disease Angelman's syndrome Mitral valve incompetence Cortical dysplasia BK virus infection Neurogenic bladder Epicondylitis Diphtheria Vesicoureteric reflux Ectopic pregnancy H1N1 influenza Gastric cancer stage IV More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Focal segmental glomerulosclerosis

  • A study to evaluate the effects of BI 764198 in adults and adolescents with focal segmental glomerulosclerosis (FSGS)

    Recruiting

    3 1
    Investigated Diseases:
    • Focal segmental glomerulosclerosis
    Investigated Drugs:
    • [4-(6-Aminopyridazin-3-Yl)Piperidin-1-Yl][5-(4-Fluorophenoxy)-4-Methoxypyridin-2-Yl]Methanone
    Belgium Croatia Denmark France Germany Greece +9

  • Study of Atacicept Treatment for Patients with Multiple Autoimmune Glomerular Diseases

    Recruiting

    2 1 1
    Investigated Diseases:
    • Glomerulonephritis membranous
    • Nephrotic syndrome
    • Focal segmental glomerulosclerosis
    Investigated Drugs:
    • Atacicept
    Belgium France Germany Italy Poland Spain

  • Study on Frexalimab, SAR442970, and Rilzabrutinib for Patients Aged 16-75 with Focal Segmental Glomerulosclerosis or Minimal Change Disease

    Recruiting

    2 1
    Investigated Diseases:
    • Glomerulonephritis minimal lesion
    • Focal segmental glomerulosclerosis
    Czechia France Germany Greece Hungary Italy +5

  • Study on the Safety and Effects of Sparsentan for Children with Proteinuric Kidney Diseases

    Recruiting

    2 1 1
    Investigated Diseases:
    • Glomerulonephritis minimal lesion
    • Focal segmental glomerulosclerosis
    • IgA nephropathy
    Investigated Drugs:
    • Sparsentan
    Germany Italy The Netherlands Poland Spain Sweden

  • Efficacy and Safety of Pegcetacoplan in Adults and Adolescents with Focal Segmental Glomerulosclerosis: Phase 2/3 Open‑Label and Randomized Placebo‑Controlled Study

    Not yet recruiting

    4 1 1
    Investigated Diseases:
    • Focal segmental glomerulosclerosis
    Investigated Drugs:
    • Pegcetacoplan
    France Germany Italy Poland Portugal Slovakia +1

  • Study on the Effects of Sparsentan and Irbesartan for Patients with Primary Focal Segmental Glomerulosclerosis (FSGS)

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Focal segmental glomerulosclerosis
    Investigated Drugs:
    • Irbesartan
    • Sparsentan
    Belgium Croatia Czechia Denmark Estonia France +6
1 2
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!